Results 211 to 220 of about 28,987 (300)

Real-world effectiveness of high-efficacy therapies in multiple sclerosis: a propensity score-matched cohort study. [PDF]

Front Neurol
Wich J, Beppler T, Dreiling M, Scherag A, Schwab M, Rakers F.   +5 more
europepmc   +1 more source

Ethics and equity in access to disease‐modifying therapies and newborn screening for spinal muscular atrophy: A scoping review

Developmental Medicine &Child Neurology, EarlyView.
Outcomes of children with cerebral palsy receiving long‐term respiratory support. Aim To review barriers to ethical and equitable access to disease‐modifying therapies (DMTs) and newborn screening (NBS) for spinal muscular atrophy (SMA). Method We searched PubMed, Scopus, Web of Science, EBSCOhost, the Cochrane Library, Google Scholar, and Primo for ...
Serini Murugasen, Mariana Kruger, Marc Blockman, Jo M. Wilmshurst   +3 more
wiley   +1 more source

Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy. [PDF]

J Neurol
Penner IK, Maier T, Wiemer T, Leemhuis J, Weber E, Schreiber H, Ziemssen T.   +6 more
europepmc   +1 more source

Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study

European Journal of Haematology, EarlyView.
ABSTRACT Background Real‐world data on transfusion needs of patients with myelodysplastic syndromes (MDS), and the impacts of disease‐modifying therapies (DMTs) are sparse. In 2011, 5‐azacitidine became the first funded DMT for MDS and chronic myelomonocytic leukaemia (CMML) patients in Australia and national patient blood management (PBM) guidelines ...
Allison Mo, Le Thi Phuong Thao, Cameron Wellard, Erica M. Wood, Jake Shortt, Zoe K. McQuilten   +5 more
wiley   +1 more source

Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study. [PDF]

Neurotherapeutics
Brummer T, Räuber S, Jakob J, Willison AG, Schraad M, Protopapa M, Fleischer MI, Boeckers JM, Ruck T, Meuth SG, Zipp F, Fleischer V, Bittner S.   +12 more
europepmc   +1 more source

Project Sickle Cure: A Prospective, International Observational Study of Hematopoietic Cell Transplantation for Sickle Cell Disease

European Journal of Haematology, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) is a chronic and life‐limiting hemoglobin and systemic vascular disease. While over 1000 people have undergone hematopoietic cell transplantation (HCT) over the last 40 years, long‐term disease‐specific and health‐related quality of life data are lacking.
Gregory M. T. Guilcher, Allistair Abraham, Staci D. Arnold, Christine Camacho‐Bydume, Jenny Duong, Scott Gillespie, Ann Haight, Monica L. Hulbert, Naresh Kumar, Katie Liu, Cherry Mammen, Aleksandra Mineyko, Abra Morgan, Alexander Ngwube, Robert S. Nickel, Araby Roberts, Fiona Schulte, Stephen Sands, Akshay Sharma, John T. Horan, Elizabeth O. Stenger   +20 more
wiley   +1 more source

Long‐term outcome of a non‐reducible congenital atlanto‐occipital subluxation in a warmblood foal

Equine Veterinary Education, EarlyView.
Summary An 11‐day‐old warmblood colt was referred to the Large Animal Teaching Hospital, University of Copenhagen, for further investigation of a stiff neck and lateral deviation of the poll, with suspicion of a congenital cervical vertebral abnormality.
D. M. T. Adler, S. Hansen, L. Rasmussen, S. Jacobsen   +3 more
wiley   +1 more source

Computational spirits: a neuroscientific account of psychedelic entity encounters. [PDF]

Neurosci Conscious
Mago J, Deane G, Sandved-Smith L, Safron A, Timmermann C, Ramstead M, Dupuis D, Carhart-Harris R, Greenway KT, Lifshitz M.   +9 more
europepmc   +1 more source

1H NMR metabolomics and lipidomics analysis of neutrophils reveals biomarkers of ageing, inflammageing and frailty

The FEBS Journal, EarlyView.
Using 1H NMR metabolomics, we measured polar and lipid metabolites from human blood neutrophils from people with frailty (n = 31, mean age 84Y), people with rheumatoid arthritis (n = 16, mean age 55Y), robust older (n = 24, mean age 66Y) and healthy younger people (n = 21, mean age 22Y).
Genna Ali Abdullah, Grace Filbertine, Lucy Gill, Asangaedem Akpan, Marie M. Phelan, Helen Louise Wright   +5 more
wiley   +1 more source